Metrics as of 10/15/2026, 08:48 PM (Berlin time), refresh in progress.
Clene Stock
Clene Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Etherington
- Employees
- 78
- Market cap
- $47 M
- IPO
- 18/10/2018
- Web
- clene.com
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of…
Clene stock: price history
1D
+0.5%
1W
-14.3%
1M
-17.3%
6M
-47.6%
YTD
-43.4%
1Y
-62.6%
2Y
-43.2%
5Y
-97.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~37% stronger price swings than usual
Ask the agents about Clene
Analyst assessment of Clene
PRICE TARGET LOW
US$50.00
CONSENSUS
US$50.00
MEDIAN
US$50.00
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 04/05/2026
Clene stock metrics
P/E
-0.94
P/B
-1.66
EV/EBITDA
-2.15
RETURN ON EQUITY
54.2%
NET MARGIN
-14,915.6%
DEBT/EQUITY
-0.9
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.3%
FLOAT SHARES
9,701,655
AVG. DAILY VOLUME (30D)
127,074
Insider transactions (SEC)
Etherington Robert Dee
Mosca Alison
MATLIN DAVID J
Ugwumba Chidozie
Ugwumba Chidozie
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Clene stock
What does Clene do?
Clene Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Etherington, the company employs around 78 people.
The IPO was on 18/10/2018; the stock trades on NASDAQ under the ticker CLNN.
What do analysts say about Clene stock?
8 analysts rate the stock, the consensus is Buy (as of 04/05/2026).
The average price target is US$50.00, ranging from US$50.00 to US$50.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does Clene report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 37% stronger than usual.
Does Clene pay a dividend?
No, Clene currently does not pay a dividend.
Which stocks are comparable to Clene?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Clene stock analyzed?
Clicking "Analyze stock" lets five strategies assess Clene against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.